BR112018071186A2 - rna, pluralidade de rnas, construto de interferência por rna dirigida por dna, composição, método para inibir a expressão de uma proteína, método para tratar distrofia muscular oculofaríngea e kit - Google Patents
rna, pluralidade de rnas, construto de interferência por rna dirigida por dna, composição, método para inibir a expressão de uma proteína, método para tratar distrofia muscular oculofaríngea e kitInfo
- Publication number
- BR112018071186A2 BR112018071186A2 BR112018071186-1A BR112018071186A BR112018071186A2 BR 112018071186 A2 BR112018071186 A2 BR 112018071186A2 BR 112018071186 A BR112018071186 A BR 112018071186A BR 112018071186 A2 BR112018071186 A2 BR 112018071186A2
- Authority
- BR
- Brazil
- Prior art keywords
- muscular dystrophy
- rna
- rnas
- dna
- kit
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title abstract 3
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 title 1
- 230000009368 gene silencing by RNA Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 108091030071 RNAI Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 101150003773 pabpn1 gene Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente revelação refere-se a reagentes de interferência por rna (rnai) que têm como alvo pabpn1 para tratamento de distrofia muscular oculofaríngea (opmd), composições que compreendem os mesmos e uso dos mesmos para tratar indivíduos que sofrem de opmd ou que são predispostos à mesma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662322745P | 2016-04-14 | 2016-04-14 | |
US62/322,745 | 2016-04-14 | ||
PCT/AU2017/050330 WO2017177277A1 (en) | 2016-04-14 | 2017-04-13 | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018071186A2 true BR112018071186A2 (pt) | 2019-02-12 |
BR112018071186A8 BR112018071186A8 (pt) | 2023-03-28 |
Family
ID=60041243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018071186A BR112018071186A8 (pt) | 2016-04-14 | 2017-04-13 | Rna, pluralidade de rnas, construto de interferência por rna dirigida por dna, composição, método para inibir a expressão de uma proteína, método para tratar distrofia muscular oculofaríngea e kit |
Country Status (15)
Country | Link |
---|---|
US (1) | US11234994B2 (pt) |
EP (1) | EP3443091A4 (pt) |
JP (1) | JP7236195B2 (pt) |
KR (1) | KR102353847B1 (pt) |
CN (1) | CN109219659B (pt) |
AU (1) | AU2017250017B2 (pt) |
BR (1) | BR112018071186A8 (pt) |
CA (1) | CA3020754C (pt) |
IL (1) | IL262337B2 (pt) |
MX (1) | MX2018012545A (pt) |
NZ (1) | NZ747314A (pt) |
RU (1) | RU2755544C2 (pt) |
SG (1) | SG11201808981XA (pt) |
WO (1) | WO2017177277A1 (pt) |
ZA (1) | ZA201807589B (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2755544C2 (ru) | 2016-04-14 | 2021-09-17 | Бенитек Биофарма Лимитед | Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение |
EP3555294A4 (en) | 2016-12-14 | 2020-08-26 | Benitec Biopharma Limited | REAGENTS FOR TREATMENT OF OKULOPHARYNGEAL MUSCLE DYSTROPHY (OPMD) AND USES THEREOF |
CN112867511A (zh) * | 2018-10-17 | 2021-05-28 | 贝尼泰克生物制药有限公司 | 用于治疗眼咽肌营养不良(opmd)的方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
CA2088673A1 (en) | 1990-08-03 | 1992-02-04 | Alexander L. Weis | Compounds and methods for inhibiting gene expression |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
AU6412794A (en) | 1993-03-31 | 1994-10-24 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
CA2317549C (en) | 1998-01-05 | 2006-04-11 | University Of Washington | Composition for enhancing transport through lipid-containing membranes, and uses thereof |
US7273933B1 (en) | 1998-02-26 | 2007-09-25 | Isis Pharmaceuticals, Inc. | Methods for synthesis of oligonucleotides |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
WO2001053307A1 (en) | 2000-01-21 | 2001-07-26 | Geron Corporation | 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use |
WO2002018405A2 (en) | 2000-09-01 | 2002-03-07 | Ribozyme Pharmaceuticals, Incorporated | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
EP2017338A1 (en) | 2001-05-24 | 2009-01-21 | Genzyme Corporation | Muscle-specific expression vectors |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US6989442B2 (en) | 2002-07-12 | 2006-01-24 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
RU2005106999A (ru) | 2002-08-29 | 2005-08-27 | Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити (Us) | Кольцевые векторы нуклеиновой кислоты и способы их создания и использования |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US7358223B2 (en) | 2004-10-04 | 2008-04-15 | Nitto Denko Corporation | Biodegradable cationic polymers |
EP1838853A2 (en) * | 2005-01-06 | 2007-10-03 | Benitec, Inc. | Rnai agents for maintenance of stem cells |
WO2007086881A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
US8110184B2 (en) * | 2005-09-30 | 2012-02-07 | University Of Kentucky Research Foundation | Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations |
EP2014281A1 (en) * | 2007-06-19 | 2009-01-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. |
EP2326331A4 (en) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION |
EP2350043B9 (en) | 2008-10-09 | 2014-08-20 | TEKMIRA Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
JP6032724B2 (ja) | 2009-03-12 | 2016-11-30 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法 |
WO2011022460A1 (en) | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Novel cationic lipids with various head groups for oligonucleotide delivery |
WO2011098449A1 (en) * | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
UY33851A (es) | 2010-12-30 | 2012-07-31 | Dow Agrosciences Llc | Moléculas de ácido nucleico que confieren resistencia a las plagas de coleópteros |
KR101454425B1 (ko) | 2012-10-11 | 2014-11-03 | 포항공과대학교 산학협력단 | 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물 |
WO2014077693A1 (en) | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
KR101683964B1 (ko) | 2014-05-29 | 2016-12-09 | 연세대학교 산학협력단 | Daxx의 발현을 억제하는 핵산 분자, TRAIL 유전자 및 Bcl-xL 의 발현을 억제하는 핵산 분자를 포함하는 재조합 발현 벡터 |
RU2755544C2 (ru) | 2016-04-14 | 2021-09-17 | Бенитек Биофарма Лимитед | Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение |
-
2017
- 2017-04-13 RU RU2018138271A patent/RU2755544C2/ru active
- 2017-04-13 EP EP17781644.4A patent/EP3443091A4/en active Pending
- 2017-04-13 SG SG11201808981XA patent/SG11201808981XA/en unknown
- 2017-04-13 AU AU2017250017A patent/AU2017250017B2/en active Active
- 2017-04-13 CN CN201780034592.0A patent/CN109219659B/zh active Active
- 2017-04-13 MX MX2018012545A patent/MX2018012545A/es unknown
- 2017-04-13 WO PCT/AU2017/050330 patent/WO2017177277A1/en active Application Filing
- 2017-04-13 BR BR112018071186A patent/BR112018071186A8/pt active Search and Examination
- 2017-04-13 CA CA3020754A patent/CA3020754C/en active Active
- 2017-04-13 US US16/093,493 patent/US11234994B2/en active Active
- 2017-04-13 JP JP2018554006A patent/JP7236195B2/ja active Active
- 2017-04-13 KR KR1020187032992A patent/KR102353847B1/ko active IP Right Grant
- 2017-04-13 NZ NZ747314A patent/NZ747314A/en unknown
-
2018
- 2018-10-14 IL IL262337A patent/IL262337B2/en unknown
- 2018-11-12 ZA ZA2018/07589A patent/ZA201807589B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017177277A1 (en) | 2017-10-19 |
AU2017250017A1 (en) | 2018-11-08 |
AU2017250017B2 (en) | 2022-12-22 |
JP2019513395A (ja) | 2019-05-30 |
CA3020754A1 (en) | 2017-10-19 |
BR112018071186A8 (pt) | 2023-03-28 |
RU2018138271A3 (pt) | 2020-09-22 |
RU2018138271A (ru) | 2020-05-14 |
CN109219659B (zh) | 2022-09-09 |
US11234994B2 (en) | 2022-02-01 |
CN109219659A (zh) | 2019-01-15 |
NZ747314A (en) | 2022-07-29 |
EP3443091A1 (en) | 2019-02-20 |
EP3443091A4 (en) | 2019-11-27 |
JP7236195B2 (ja) | 2023-03-09 |
IL262337A (en) | 2018-11-29 |
ZA201807589B (en) | 2023-02-22 |
KR20180133500A (ko) | 2018-12-14 |
US20200138849A1 (en) | 2020-05-07 |
CA3020754C (en) | 2023-07-25 |
KR102353847B1 (ko) | 2022-01-21 |
MX2018012545A (es) | 2019-06-10 |
IL262337B2 (en) | 2023-06-01 |
RU2755544C2 (ru) | 2021-09-17 |
SG11201808981XA (en) | 2018-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018011450A2 (pt) | métodos e composições para o tratamento de um transtorno associado à serpinc1 | |
BR112019005548A2 (pt) | tratamento da doença de huntington com aav | |
BR112019001887A2 (pt) | composições e métodos para o tratamento de doença associada a cep290 | |
AU2018253578A1 (en) | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) | |
CO2020001354A2 (es) | Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia un arni, por ejemplo, un ácido ribonucleico de hebra doble (arnhd), composiciones dirigidas al gen serpinc1 y métodos para usar dicho arni, por ejemplo, arnhd, composiciones para tratar un evento de sangrado en un sujeto que tiene una hemofilia (por ejemplo, con o sin inhibidores). | |
WO2016106401A3 (en) | Rna agents for p21 gene modulation | |
BR112021019793A2 (pt) | Composições e métodos para inibir expressão de gene no sistema nervoso central | |
MX2018014152A (es) | Composiciones y métodos para tratar la enfermedad de huntington. | |
BR112018005862A2 (pt) | anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit | |
WO2017201102A8 (en) | Method of improved sequencing by strand identification | |
BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
BR112014028644A2 (pt) | Composições e métodos para modulação da expressão de atp2a2 | |
EA201790420A1 (ru) | Средства, представляющие собой модифицированную двухнитевую рнк | |
EA201490993A1 (ru) | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
BR112019010342A2 (pt) | composições do irna de serpina1 e métodos de uso destas | |
BR112013027774A2 (pt) | novos compostos como moduladores de proteína quinases | |
ATE548454T1 (de) | Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis | |
BR112018071186A2 (pt) | rna, pluralidade de rnas, construto de interferência por rna dirigida por dna, composição, método para inibir a expressão de uma proteína, método para tratar distrofia muscular oculofaríngea e kit | |
BR112021024080A2 (pt) | Construtos de rnai para inibir a expressão de scap e métodos de uso dos mesmos | |
WO2010111503A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF THE HIGH AFFINITY IGE RECEPTOR ALPHA CHAIN (FCεRLα) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | |
BR112018010669A8 (pt) | anticorpo anti-pcsk9 e utilização do mesmo | |
BR112021021686A2 (pt) | Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas | |
IL292053A (en) | Preparations, methods and kits for stabilizing a biological sample and RNA | |
BR112019012312A8 (pt) | Reagentes para tratamento da distrofia muscular oculofaríngea (opmd) e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BENITEC BIOPHARMA PTY LTD (AU) |
|
B25G | Requested change of headquarter approved |
Owner name: BENITEC BIOPHARMA PTY LTD (AU) |
|
B25A | Requested transfer of rights approved |
Owner name: BENITEC IP HOLDINGS INC. (US) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |